Cross Country Healthcare (CCRN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 May, 2026Executive summary
Agreement reached to be acquired by Knox Lane, transitioning to a private company upon closing.
Transaction aims to provide immediate value to shareholders and enhance operational flexibility.
Leadership emphasizes continuity in mission, values, and commitment to employees and clients.
Forward-looking statements highlight anticipated benefits and strategic opportunities post-acquisition.
Voting matters and shareholder proposals
Shareholder approval required for the proposed merger with Knox Lane.
Proxy solicitation involves directors, executive officers, and related participants.
Board of directors and corporate governance
Board considered multiple factors, including culture and partnership, in approving the merger.
Directors and executive officers are participants in the proxy solicitation process.
Latest events from Cross Country Healthcare
- Q1 2026 revenue dropped 17.8% and net loss widened, as merger plans to go private were announced.CCRN
Q1 20268 May 2026 - Shareholders to vote on $437M all-cash acquisition by Knox Lane, with no operational changes expected.CCRN
Proxy filing7 May 2026 - Transition to private ownership by Knox Lane at $13.25 per share, pending shareholder approval.CCRN
Proxy filing7 May 2026 - All shares to be acquired for $13.25 cash in a $437M deal, pending shareholder approval.CCRN
Proxy filing7 May 2026 - Supplement clarifies Amended Plan benefits; Board maintains support for Proposal 4.CCRN
Proxy filing2 Apr 2026 - Proxy details leadership change, tech-driven strategy, and key votes on governance and compensation.CCRN
Proxy filing30 Mar 2026 - Virtual annual meeting to vote on directors, auditor, compensation, and incentive plan.CCRN
Proxy filing30 Mar 2026 - 2025 saw revenue and profit declines, but 2026 is set for sequential growth and margin gains.CCRN
Q4 20255 Mar 2026 - Q2 revenue fell 37% to $339.8M, with net loss of $16.1M but strong cash flow and tech gains.CCRN
Q2 20242 Feb 2026